Moderna will present safety data on Wednesday from an early trial that provides the first glimpse of how its Covid-19 vaccine stimulates the immune system in older people.

The company will present “new interim safety and immunogenicity data from the cohorts of older adults” from its phase 1 trial, according to a statement. The results will be presented to the US Center for Disease Control and Prevention’s Advisory Committee on Immunisation Practices...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now